Loci showing recurrent allelic imbalances according to WHO classification of thymic tumors
| Locus . | Gene . | WHO thymoma typea . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | . | A . | AB . | B2 . | B3 . | C . | ||||
| 3p14.2 | FHIT | (16%) | ||||||||
| 5q21-22 | APC | 33%b | (16%)* | |||||||
| 6p21.3 | MHC | 27% | 25% | 41% | 75% | |||||
| 6q14-15 | 27% | 37% | 75% | |||||||
| 6q21 | 33% | |||||||||
| 6q25.2-25.3 | 36% | 37% | 33% | 39% | 100% | |||||
| 7p15.3 | 50% | |||||||||
| 8p11.21 | 33% | 30% | ||||||||
| 13q14.3 | RB | 27% | 28%* | |||||||
| 16q22.1 | CDH1 | 50% | 50% | |||||||
| 16q23-24.1 | 50% | |||||||||
| 17p13.1 | p53 | (16%)* | ||||||||
| Locus . | Gene . | WHO thymoma typea . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | . | A . | AB . | B2 . | B3 . | C . | ||||
| 3p14.2 | FHIT | (16%) | ||||||||
| 5q21-22 | APC | 33%b | (16%)* | |||||||
| 6p21.3 | MHC | 27% | 25% | 41% | 75% | |||||
| 6q14-15 | 27% | 37% | 75% | |||||||
| 6q21 | 33% | |||||||||
| 6q25.2-25.3 | 36% | 37% | 33% | 39% | 100% | |||||
| 7p15.3 | 50% | |||||||||
| 8p11.21 | 33% | 30% | ||||||||
| 13q14.3 | RB | 27% | 28%* | |||||||
| 16q22.1 | CDH1 | 50% | 50% | |||||||
| 16q23-24.1 | 50% | |||||||||
| 17p13.1 | p53 | (16%)* | ||||||||
Type: histological type according to the WHO classification of thymic tumors (4).
Percentage (%): loci showing recurrent LOHs or amplification in at least 25% of informative cases in each thymoma type.
Combined LOHs in three advanced B3 thymomas (stage III-IVA): case nos. 44, 45, 46. In addition, case nos. 44 and 46 shared the LOH at 3p14.2 (FHIT; Fig. 3). Percentages of LOHs in this subset of B3 thymomas are given in brackets when <25%.